Literature DB >> 17304542

First trimester ultrasonography in screening and detection of fetal anomalies.

Jiri Sonek1.   

Abstract

An obstetrical ultrasound examination provides invaluable information regarding the fetus. Until the mid-1980s, ultrasound in the first trimester was limited to localization of the pregnancy, establishing viability, and accurate dating. With the advent of high-resolution ultrasound and transvaginal scanning, a significant amount of information about the fetus can be gained and provided to the patient at a very early stage in gestation. This article provides an overview of the role of first trimester (11-13 + 6 weeks' gestation) ultrasound in screening and diagnosis of fetal anomalies. The first trimester is an ideal time for screening for aneuploidy, primarily due to the advantages that nuchal translucency (NT) measurement provides. NT measurement is also useful in establishing the risk of congenital cardiac disorders and a number of genetic and non-genetic syndromes. Significant NT thickening is associated with an increase in perinatal morbidity and mortality. Potential mechanisms resulting in increased NT are discussed. A number of new ultrasound markers for fetal aneuploidy have been investigated over the past several years, some of which appear to improve the screening efficacy of early ultrasonography. The role of these is reviewed. A number of fetal anomalies can now be consistently diagnosed in the first trimester. Their appearance at this early gestational age is discussed as well. It is clear that, data obtained by first trimester ultrasound are useful in counseling expectant parents and in planning the appropriate follow-up. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17304542     DOI: 10.1002/ajmg.c.30120

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  7 in total

1.  Microarrays as a diagnostic tool in prenatal screening strategies: ethical reflection.

Authors:  Antina de Jong; Wybo J Dondorp; Merryn V E Macville; Christine E M de Die-Smulders; Jan M M van Lith; Guido M W R de Wert
Journal:  Hum Genet       Date:  2014-02       Impact factor: 4.132

Review 2.  Advances in prenatal screening: the ethical dimension.

Authors:  Antina de Jong; Wybo J Dondorp; Suzanna G M Frints; Christine E M de Die-Smulders; Guido M W R de Wert
Journal:  Nat Rev Genet       Date:  2011-08-18       Impact factor: 53.242

3.  MicroRNA biomarkers for early detection of embryonic malformations in pregnancy.

Authors:  Xuezheng Li; Zhiyong Zhao
Journal:  J Biomol Res Ther       Date:  2014-12

Review 4.  Adults with genetic syndromes and cardiovascular abnormalities: clinical history and management.

Authors:  Angela E Lin; Craig T Basson; Elizabeth Goldmuntz; Pilar L Magoulas; Deborah A McDermott; Donna M McDonald-McGinn; Elspeth McPherson; Colleen A Morris; Jacqueline Noonan; Catherine Nowak; Mary Ella Pierpont; Reed E Pyeritz; Alan F Rope; Elaine Zackai; Barbara R Pober
Journal:  Genet Med       Date:  2008-07       Impact factor: 8.822

5.  First-Trimester Crown-Rump Length and Embryonic Volume of Fetuses with Structural Congenital Abnormalities Measured in Virtual Reality: An Observational Study.

Authors:  L Baken; B Benoit; A H J Koning; P J van der Spek; E A P Steegers; N Exalto
Journal:  Biomed Res Int       Date:  2017-03-21       Impact factor: 3.411

6.  Study on the application of ultrasonography in the diagnosis of fetal cardiac structural abnormalities and the relationship between fetal cardiac structural abnormalities with chromosome abnormalities in early pregnancy.

Authors:  Xueqin Ji; Yan Xia; Hao Zhang; Hairui Wang; Ruixian Shi; Zhen Han
Journal:  Ann Transl Med       Date:  2021-12

7.  First trimester diagnosis and screening for fetal aneuploidy.

Authors:  Deborah A Driscoll; Susan J Gross
Journal:  Genet Med       Date:  2008-01       Impact factor: 8.822

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.